There are 2949 resources available
1080MO - The value of local therapy in treatment of solitary melanoma progression upon immune checkpoint inhibition
Presenter: Judith Versluis
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1081MO - Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Presenter: Anna Di Giacomo
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA48 - Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial
Presenter: Inge-Marie Svane
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1082MO - 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone
Presenter: Caroline Robert
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1083MO - Final results from ILLUMINATE-204, a phase I/II trial of intratumoral tilsotolimod in combination with ipilimumab in PD-1 inhibitor refractory advanced melanoma
Presenter: Cara Haymaker
Session: Mini Oral - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
529MO - Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
Presenter: Mohamed Gouda
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
530MO - Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Presenter: Emiliano Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
531MO - VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
532MO - A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour
Presenter: Ying Cheng
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
533MO - Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Presenter: Nicolas Girard
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast